Start-up Lost Time and its Effect on Signalized Intersections in Turkey

Start-up lost time is an important parameter in performance of signalized intersections which may in turn depict the effect of behaviour of different drivers for different countries. In this study the parameters affecting the startup lost time in Turkey will be defined and a model will be established to present the relationship between start-up lost time, saturation flow as well as start response time with the behaviour of Turkish drivers. For this purpose, observations were carried out at eight intersections in Turkey. Analyses have shown that saturation headways decrease with the increase in time in start response since the drivers in the 2nd and higher rows of a queue have a longer time to get prepared to discharge. Results also indicated that start-up lost time increases rapidly as cycle time increases, and lower start-up lost time values can be observed in left or right turning lanes.</p

Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium

Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder with recurrent fever, abdominal pain, serositis, articular manifestations, erysipelas-like erythema, and renal complications as its main features. Caused by the mutations in the MEditerranean FeVer (MEFV) gene, it mainly affects people of Mediterranean descent with a higher incidence in the Turkish, Jewish, Arabic, and Armenian populations. As our understanding of FMF improves, it becomes clearer that we are facing with a more complex picture of FMF with respect to its pathogenesis, penetrance, variant type (gain-of-function vs. loss-of-function), and inheritance. In this study, MEFV gene analysis results and clinical findings of 27,504 patients from 35 universities and institutions in Turkey and Northern Cyprus are combined in an effort to provide a better insight into the genotype-phenotype correlation and how a specific variant contributes to certain clinical findings in FMF patients. Our results may help better understand this complex disease and how the genotype may sometimes contribute to phenotype. Unlike many studies in the literature, our study investigated a broader symptomatic spectrum and the relationship between the genotype and phenotype data. In this sense, we aimed to guide all clinicians and academicians who work in this field to better establish a comprehensive data set for the patients. One of the biggest messages of our study is that lack of uniformity in some clinical and demographic data of participants may become an obstacle in approaching FMF patients and understanding this complex disease